Nanotechnology regulation in Canada, the United States, and the European Union

Introduction to the webinar series
Marie D’Iorio, President, NanoCanada

Update on Nanomaterial Regulatory Development Under the Canadian Environmental Protection Act (CEPA)
Djordje Vladisavljevic, Health Canada

Nanoscale Materials Under TSCA
Alexandria Stanton, US EPA

Nanotechnology regulatory updates in the European Union
Kimberly Ong, Vireo

Panel/questions for speakers
All Speakers

Closing remarks
Marie D’Iorio, President, NanoCanada

Djordje Vladisavljevic
Head of Nanotechnology Section at Health Canada (HC/SC)

'Update on Nanomaterial Regulatory Development Under CEPA'

Djordje has been with the New Substances Assessment and Control Bureau since 2017 conducting pre-market human health risk assessment and management of manufactured nanomaterials. With the Nanotechnology Section, Djordje has worked to develop and shepherd new policies shaping Health Canada’s response to new and existing nanomaterials under the Canadian Environmental Protection Act. Prior to entering the world of risk assessment, Djordje worked with the National Biomonitoring Section and the Canadian Health Measures Survey, coordinating measurement and analysis of body burdens of environmental pollutants in Canadians. Djordje began his career with the Government of Canada in 2009 as a research biologist in the Inhalation Toxicology Laboratory at Health Canada looking at systemic health impacts of inhaled particulate, including ultrafine fraction nanoparticles.

Alexandria Stanton
Chemist at the US Environmental Protection Agency (EPA)

'Nanoscale Materials Under TSCA'

Dr. Alexandria Stanton is a program manager for the Toxic Substances Control Act (TSCA) Section 5 new chemical notice review and risk management process. She has served with the Environmental Protection Agency for four years and specializes in “interesting” chemical classes, such as nanomaterials, mixed metal oxides, and photopolymer additives. With an eye towards understanding the potential risks of nanomaterials to human health and the environment, Dr. Stanton develops international standards and test guidelines as a representative to the International Standards Organization Technical Committee 229 and as the US Head of Delegation to the Organization for Economic Co-operation and Development (OECD) Working Party for Manufactured Nanomaterials, and communicates daily with stakeholders on issues of working protection and comprehension of chemical hazard and risk.

Kimberly Ong
Toxicologist, Vireo Advisors, LLC

'Nanotechnology regulatory updates in the European Union' 

Dr. Kimberly Ong is an expert in nanomaterial research and toxicology, particularly in protocol development, standard testing, and alternative test development. Kim has experience assessing and modifying protocols specific for nanomaterials’ testing to improve reliability for risk and exposure assessment. She supports safe and sustainable development of new technologies and products, and helps companies meet stakeholder safety requirements, including regulatory review. She works with companies and organizations to characterize any potential human health or environmental hazards of new and emerging materials to inform decision making. Kim is versed in current and proposed risk assessment frameworks for nanomaterials and has a detailed working knowledge of international regulatory requirements for new and emerging substances, including nanomaterials. Kim is a committee member of NanoCanada’s Canadian Safety and Health Initiative for Nanotechnology and Advanced Materials (CASHINAM).